Du Chunling, Lu Jinchang, Zhou Lei, Wu Bo, Zhou Feng, Gu Liang, Xu Donghui, Sun Yingxin
Department of Respiratory Medicine, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, China.
Int J Chron Obstruct Pulmon Dis. 2017 Nov 21;12:3341-3351. doi: 10.2147/COPD.S143279. eCollection 2017.
To explore the effect of cigarette smoke (CS) on the development of squamous metaplasia in human airway epithelial cells and the role of MAPK- and FoxA2-signaling pathways in the process.
In an in vitro study, we treated the bronchial epithelial cell line BEAS2B with CS extract, followed by treatment with the ERK inhibitor U0126, the JNK inhibitor SP600125, or the p38 inhibitor SB203580. In vivo, we used a CS-induced rat model. After treatment with CS with or without MAPK inhibitors for 90 days, lung tissues were harvested. p-ERK, p-p38 and p-JNK protein levels in cells and lung tissue were measured using enzyme-linked immunosorbent assays, mRNA- and protein-expression profiles of FoxA2, E-cadherin, CD44, and ZO1 were measured using quantitative real-time polymerase chain reaction and Western blotting, respectively, and morphological changes in bronchial epithelial cells were observed using lung-tissue staining.
In both the in vitro and in vivo studies, phosphorylation of the ERK1/2, JNK, and p38 proteins was significantly increased (<0.05) and mRNA and protein expression of E-cadherin and FoxA2 significantly decreased (<0.05) compared with the control group. ERK, JNK, and p38 inhibitors reversed the CS-extract-induced changes in E-cadherin, CD44, and ZO1 mRNA and protein expression (<0.05), decreased p-ERK, p-p38, and p-JNK protein levels in cells and lung tissue, suppressed bronchial epithelial hyperplasia and local squamous metaplasia, and decreased FoxA2 expression.
MAPK and FoxA2 mediate CS-induced squamous metaplasia. MAPK inhibitors upregulate FoxA2, resulting in a reduction in the degree of squamous metaplasia.
探讨香烟烟雾(CS)对人气道上皮细胞鳞状化生发展的影响以及丝裂原活化蛋白激酶(MAPK)和叉头框蛋白A2(FoxA2)信号通路在此过程中的作用。
在一项体外研究中,我们用CS提取物处理支气管上皮细胞系BEAS2B,随后用细胞外信号调节激酶(ERK)抑制剂U0126、应激活化蛋白激酶(JNK)抑制剂SP600125或p38抑制剂SB203580进行处理。在体内实验中,我们使用CS诱导的大鼠模型。在用CS处理90天(有无MAPK抑制剂)后,采集肺组织。使用酶联免疫吸附测定法测量细胞和肺组织中磷酸化ERK(p-ERK)、磷酸化p38(p-p38)和磷酸化JNK(p-JNK)蛋白水平,分别使用定量实时聚合酶链反应和蛋白质印迹法测量FoxA2、E-钙黏蛋白、CD44和紧密连接蛋白1(ZO1)的mRNA和蛋白表达谱,并使用肺组织染色观察支气管上皮细胞的形态变化。
在体外和体内研究中,与对照组相比,ERK1/2、JNK和p38蛋白的磷酸化均显著增加(<0.05),E-钙黏蛋白和FoxA2的mRNA及蛋白表达均显著降低(<0.05)。ERK、JNK和p38抑制剂逆转了CS提取物诱导的E-钙黏蛋白、CD44和ZO1 mRNA及蛋白表达的变化(<0.05),降低了细胞和肺组织中p-ERK、p-p38和p-JNK蛋白水平,抑制了支气管上皮增生和局部鳞状化生,并降低了FoxA2表达。
MAPK和FoxA2介导CS诱导的鳞状化生。MAPK抑制剂上调FoxA2,导致鳞状化生程度降低。